Thus, the antiproliferative effect of PAC+ATRA treatment on ADPKD cells is assumed to be mainly mediated through the suppression of the ERK signaling but not the classical MEK/ERK pathway. The gene discussed is MAP2K7; the disease is autosomal dominant polycystic kidney disease.